Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Chinese Medical Journal

• Publication date

  2009-04-20

• Fields of study

  Medicine

• Identifiers
  PMID 19493408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Functional Outcome Scales in Traumatic Brain Injury: A Comparison of the Glasgow Outcome Scale (Extended) and the Functional Status Examination

  2005cited by this paper
• Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling.

  2004cited by this paper
• Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?

  2003cited by this paper
• Such stuff as dreams are made on: mediator-directed therapy in sepsis

  2003cited by this paper
• 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

  2003cited by this paper
• The epidemiology of sepsis in the United States from 1979 through 2000.

  2003cited by this paper
• Evaluation of Ranson, Glasgow, APACHE-II, and APACHE-O criteria to predict severity in acute biliary pancreatitis.

  2001cited by this paper
• Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care

  2001cited by this paper
• Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes.

  2001cited by this paper
• Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations.

  2000cited by this paper
• Thymosin-alpha1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model.

  1999cited by this paper
• Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial.

  1998cited by this paper
• Septic shock.

  1998cited by this paper
• Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.

  1998cited by this paper
• [Multiple organ dysfunction syndrome and multiple organ failure. Diagnosis, prognosis and therapeutic concepts].

  1998cited by this paper
• The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.

  1997cited by this paper
• Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

  1997cited by this paper
• Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

  1996cited by this paper
• Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

  1996cited by this paper
• INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

  1996cited by this paper
• Steroid controversy in sepsis and septic shock: a meta-analysis.

  1995cited by this paper
• Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome.

  1995cited by this paper
• Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature.

  1995cited by this paper
• Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

  1995cited by this paper
• CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.

  1995cited by this paper
• Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial

  1994cited by this paper
• Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

  1994cited by this paper
• Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis

  1993cited by this paper
• Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

  1991cited by this paper
• Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gram-negative infections.

  1991cited by this paper
• Radioimmunological quantitation of the urinary trypsin inhibitor in normal blood and urine.

  1989cited by this paper
• A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.

  1987cited by this paper
• Purification and biological activity of thymosin, a hormone of the thymus gland.

  1972cited by this paper

• Immunomodulatory drugs in sepsis: a systematic review and meta‐analysis

  2024cites this paper
• Pathogenesis and Management of Acute Necrotizing Encephalopathy

  2023cites this paper
• THE EFFICACY OF ULINASTATIN COMBINED WITH DEXAMETHASONE IN THE TREATMENT OF SEPSIS PATIENTS

  2023cites this paper
• Protective effect of Ulinastatin on acute lung injury in diabetic sepsis rats.

  2022cites this paper
• Effect of ulinastatin on the inflammatory response after video-assisted thoracic lobectomy in patients with lung cancer: a randomized controlled study

  2022cites this paper
• Ulinastatin as an Adjuvant Therapy to Restricting Volumes of Resuscitation Fluid Strategy for Patients with Septic Shock after Initial Management

  2021cites this paper
• Ulinastatin combined with dexamethasone can alleviate the conditions of septic patients and reduce inflammatory factor levels

  2020cites this paper
• A retrospective study of ulinastatin for the treatment of severe sepsis

  2020cites this paper
• Efficacy of ulinastatin combined with alanyl glutamine for patients with sepsis

  2020cites this paper
• GRP78/BIP/HSPA5 as a Therapeutic Target in Models of Parkinson's Disease: A Mini Review

  2019cites this paper
• Thymosin alpha 1 treatment for patients with sepsis

  2018cites this paper
• Role of using two-route ulinastatin injection to alleviate intestinal injury in septic rats

  2018cites this paper
• Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta‐analysis of Chinese and Indian patients☆,☆☆

  2017cites this paper
• Ulinastatin did not reduce mortality in elderly multiple organ failure patients: a retrospective observational study in a single center ICU

  2017cites this paper
• Anti‐inflammatory mechanism of ulinastatin: Inhibiting the hyperpermeability of vascular endothelial cells induced by TNF‐&agr; via the RhoA/ROCK signal pathway

  2017cites this paper
• The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials

  2016cites this paper
• Ulinastatin and Thymosin a1 Therapy in Adult Patients with Severe Sepsis: A Meta-analysis with Trial Sequential Analysis of Randomized Controlled Trials

  2016cites this paper
• Electroacupuncture pretreatment with different waveforms prevents brain injury in rats subjected to cecal ligation and puncture via inhibiting microglial activation, and attenuating inflammation, oxidative stress and apoptosis.

  2016cites this paper
• Sepsis and septic shock

  2016cites this paper
• The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α1 for Sepsis: A Systematic Review and Meta-Analysis

  2016cites this paper
• Ulinastatin – a newer potential therapeutic option for multiple organ dysfunction syndrome

  2016cites this paper
• Historical review of thymosin α 1 in infectious diseases

  2015cites this paper
• The Therapeutic Effects of Thymosin α1 Combined with Human Immunoglobulin (Ig) and Bundles on Severe Sepsis: a Retrospective Study.

  2015cites this paper
• Urinary trypsin inhibitor attenuates LPS-induced endothelial barrier dysfunction by upregulation of vascular endothelial-cadherin expression

  2015cites this paper
• Persistent organ dysfunction after severe sepsis: a systematic review.

  2014cites this paper
• Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study

  2014cites this paper
• Ulinastatin activates haem oxygenase 1 antioxidant pathway and attenuates allergic inflammation

  2014cites this paper
• Protective effects of ulinastatin on intestinal injury during the perioperative period of acute superior mesenteric artery ischemia.

  2014cites this paper
• Effect of Urinary Protease Inhibitor (Ulinastatin) on Cardiopulmonary Bypass: A Meta-Analysis for China and Japan

  2014cites this paper
• Matrix metalloproteinase‐8 inhibitors mitigate sepsis‐induced myocardial injury in rats

  2014cites this paper
• The Japanese guidelines for the management of sepsis

  2014cites this paper
• An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor

  2014cites this paper
• A PROSPECTIVE, RANDOMIZED STUDY USING ULINASTATIN FOR THE TREATMENT OF PATIENTS WITH SEVERE SEPSIS

  2014cites this paper
• Does Intraoperative Ulinastatin Improve Postoperative Clinical Outcomes in Patients Undergoing Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials

  2014cites this paper
• Combined therapy with methylprednisolone and ulinastatin in experimental autoimmune encephalomyelitis

  2013cites this paper
• Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications

  2013cites this paper
• The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial

  2013cites this paper
• Ulinastatin as a neuroprotective and anti‐inflammatory agent in infant piglets model undergoing surgery on hypothermic low‐flow cardiopulmonary bypass

  2013cites this paper
• Protective effects of ulinastatin on pulmonary damage in rats following scald injury.

  2012cites this paper
• Effect of ulinastatin donor-pretreatment on liver graft during cold preservation in rats.

  2011cites this paper
• Immunomodulatory therapy for sepsis: an update

  2011cites this paper
• Ulinastatin protects pulmonary tissues from lipopolysaccharide-induced injury as an immunomodulator

  2011cites this paper
• Thymus hormones as prospective anti-inflammatory agents

  2010cites this paper
• Proteomic Analysis of Pichindé virus Infection Identifies Differential Expression of Prothymosin-α

  2010cites this paper
• Urinary trypsin inhibitor: miraculous medicine in many surgical situations?

  2010cites this paper
• Ulinastatin-mediated protection against zymosan-induced multiple organ dysfunction in rats.

  2010cites this paper